Simulations Plus Q3 Revenue Jumps 10% on Strong Software, Service Demand
Ticker: SLP · Form: 10-Q · Filed: Jul 15, 2025 · CIK: 1023459
Sentiment: bullish
Topics: Pharmaceutical Software, Drug Discovery, Q3 Earnings, Revenue Growth, Life Sciences Tech, Simulation Software, Biotechnology
Related Tickers: SLP, CDMO, DTSS
TL;DR
**SLP's Q3 numbers are solid, showing consistent growth in a critical sector – buy the dip if you can.**
AI Summary
Simulations Plus, Inc. reported a robust third quarter for fiscal year 2025, with total revenue increasing to $16.5 million for the three months ended May 31, 2025, up from $15.0 million in the prior-year period, representing a 10% growth. License and maintenance revenue contributed significantly, rising to $11.0 million from $10.2 million, an 8% increase. Service revenue also saw strong growth, reaching $5.5 million compared to $4.8 million, a 15% increase. For the nine months ended May 31, 2025, total revenue climbed to $48.5 million from $44.0 million, an increase of 10.2%. The company's net income for the quarter was not explicitly detailed, but the consistent revenue growth across both segments indicates healthy operational performance. Key business changes include continued investment in intellectual property, with intangible assets related to intellectual property valued at $10.5 million as of May 31, 2025. Risks include reliance on continued demand for their simulation software and services in the pharmaceutical and biotechnology industries. The strategic outlook remains positive, focusing on expanding their software and consulting services to support drug discovery and development.
Why It Matters
This strong Q3 performance by Simulations Plus signals robust demand for its drug discovery and development software, which is critical for investors looking for growth in the life sciences tech sector. For employees, it suggests job security and potential expansion, while customers benefit from advanced simulation tools accelerating drug development. In a competitive landscape, SLP's consistent revenue growth, particularly in services, demonstrates its ability to capture market share and innovate, potentially putting pressure on competitors like Certara and Dassault Systèmes' BIOVIA.
Risk Assessment
Risk Level: medium — The company's revenue growth is positive, with a 10% increase in total revenue for the quarter. However, the filing does not explicitly detail net income or profitability, which could mask underlying cost pressures. Furthermore, the business is highly specialized in drug discovery software, making it susceptible to industry-specific downturns or shifts in pharmaceutical R&D spending.
Analyst Insight
Investors should consider holding SLP, given its consistent revenue growth and strategic position in the essential drug discovery market. Monitor upcoming earnings reports for detailed profitability metrics and any shifts in R&D spending by major pharmaceutical clients.
Financial Highlights
- revenue
- $16.5M
- revenue Growth
- +10%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| License and Maintenance | $11.0M | +8% |
| Service Revenue | $5.5M | +15% |
Key Numbers
- $16.5M — Q3 2025 Total Revenue (Up 10% from $15.0M in Q3 2024)
- 10% — Q3 2025 Revenue Growth (Year-over-year increase in total revenue)
- $11.0M — Q3 2025 License & Maintenance Revenue (Up 8% from $10.2M in Q3 2024)
- $5.5M — Q3 2025 Service Revenue (Up 15% from $4.8M in Q3 2024)
- $48.5M — Nine-Month Total Revenue (FY25) (Up 10.2% from $44.0M in prior nine-month period)
- $10.5M — Intellectual Property Intangible Assets (Value as of May 31, 2025, indicating continued investment)
Key Players & Entities
- Simulations Plus, Inc. (company) — filer of the 10-Q
- $16.5 million (dollar_amount) — total revenue for Q3 2025
- $15.0 million (dollar_amount) — total revenue for Q3 2024
- $11.0 million (dollar_amount) — license and maintenance revenue for Q3 2025
- $10.2 million (dollar_amount) — license and maintenance revenue for Q3 2024
- $5.5 million (dollar_amount) — service revenue for Q3 2025
- $4.8 million (dollar_amount) — service revenue for Q3 2024
- $48.5 million (dollar_amount) — total revenue for nine months ended May 31, 2025
- $44.0 million (dollar_amount) — total revenue for nine months ended May 31, 2024
- $10.5 million (dollar_amount) — intellectual property intangible assets as of May 31, 2025
FAQ
What were Simulations Plus's total revenues for the third quarter of fiscal year 2025?
Simulations Plus, Inc. reported total revenues of $16.5 million for the three months ended May 31, 2025, marking a 10% increase from $15.0 million in the same period last year.
How did Simulations Plus's license and maintenance revenue perform in Q3 2025?
License and maintenance revenue for Simulations Plus grew by 8% to $11.0 million in Q3 2025, up from $10.2 million in the third quarter of fiscal year 2024.
What was the growth rate for Simulations Plus's service revenue in Q3 2025?
Simulations Plus's service revenue increased by 15% to $5.5 million for the three months ended May 31, 2025, compared to $4.8 million in the prior-year period.
What were the total revenues for Simulations Plus for the first nine months of fiscal year 2025?
For the nine months ended May 31, 2025, Simulations Plus generated total revenues of $48.5 million, representing a 10.2% increase from $44.0 million in the corresponding period of fiscal year 2024.
What is the value of Simulations Plus's intellectual property intangible assets?
As of May 31, 2025, Simulations Plus reported intellectual property intangible assets valued at $10.5 million, indicating ongoing investment in their core technologies.
What are the primary revenue streams for Simulations Plus?
Simulations Plus generates revenue primarily from two segments: license and maintenance, which includes software subscriptions, and services, which encompasses consulting and research support for drug discovery and development.
What are the main risks for Simulations Plus investors?
A key risk for Simulations Plus investors is the company's specialization in the pharmaceutical and biotechnology sectors, making it vulnerable to industry-specific downturns or shifts in R&D spending by its client base.
How does Simulations Plus contribute to drug discovery?
Simulations Plus provides advanced simulation and modeling software and consulting services that help pharmaceutical and biotechnology companies accelerate drug discovery and development, reducing the need for costly and time-consuming physical experiments.
What is the strategic outlook for Simulations Plus based on this filing?
The strategic outlook for Simulations Plus appears positive, with continued focus on expanding its software and consulting services to support drug discovery and development, as evidenced by consistent revenue growth across both segments.
Should investors be concerned about Simulations Plus's profitability?
While the filing shows strong revenue growth, detailed net income and profitability figures were not explicitly provided. Investors should monitor future filings for a comprehensive understanding of the company's bottom-line performance and cost management.
Risk Factors
- Reliance on Pharmaceutical and Biotech Demand [medium — market]: The company's revenue is heavily dependent on continued investment and demand from the pharmaceutical and biotechnology industries for its simulation software and services. Any slowdown in R&D spending within these sectors could negatively impact revenue.
- Intellectual Property Investment [medium — operational]: Simulations Plus continues to invest in its intellectual property, with intangible assets valued at $10.5 million as of May 31, 2025. While this indicates a commitment to innovation, it also represents a significant asset base that requires ongoing protection and development.
Industry Context
Simulations Plus operates within the specialized software and services sector catering to the pharmaceutical and biotechnology industries. The industry is characterized by high R&D spending and a continuous need for advanced tools to accelerate drug discovery and development. Key trends include the increasing adoption of AI and machine learning in drug design and the growing complexity of regulatory requirements.
Regulatory Implications
While not a primary focus in this filing, the pharmaceutical and biotech industries are heavily regulated. Simulations Plus's software and services must align with evolving regulatory standards and data integrity requirements to remain relevant and trusted by its clients.
What Investors Should Do
- Monitor service revenue growth
- Assess R&D investment in IP
- Evaluate customer concentration risk
Glossary
- Intellectual Property
- Intangible assets that are the result of human intellect, such as patents, trademarks, and copyrights, which can be legally protected. (Represents a significant portion of the company's assets ($10.5 million as of May 31, 2025), reflecting investment in proprietary software and technology crucial for its business model.)
- License and Maintenance Revenue
- Revenue generated from the sale of software licenses and ongoing support and maintenance services for those licenses. (A core revenue stream for Simulations Plus, contributing $11.0 million in Q3 FY25, showing steady growth and customer retention.)
- Service Revenue
- Revenue derived from providing professional services, such as consulting, training, or custom development, related to the company's software products. (This segment showed strong growth of 15% to $5.5 million in Q3 FY25, indicating increasing demand for the company's expertise in drug discovery and development.)
Year-Over-Year Comparison
Simulations Plus demonstrated continued positive momentum compared to the prior year's comparable period. Total revenue grew by 10% year-over-year for the third quarter, driven by a robust 15% increase in service revenue and an 8% rise in license and maintenance revenue. This indicates sustained demand for both core software offerings and value-added consulting services, reinforcing the company's strategic focus on supporting drug discovery and development.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on July 15, 2025 regarding Simulations Plus, Inc. (SLP).